pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

UN-backed agency secures sub-licensing deals for generic Roche flu drug across 129 low- and middle-income countries

Sep 25, 2026·read at STAT ↗DealPositive

An agency supported by the United Nations has finalized sub-licensing contracts with eleven drug manufacturers to create generic versions of Roche’s influenza medication Xofluza.

The agreements allow the partners to produce and distribute the generic drug in 129 nations, encompassing almost all low- and middle-income markets.

To facilitate approval, the companies will receive technical dossiers, reference product samples for bioequivalence testing, and regulatory assistance.

The initiative aims to broaden access to an important antiviral ahead of potential flu pandemics, reflecting a push to balance commercial interests with global health needs.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic”

read at STAT ↗
496 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ROCHE5LILLYNOVOThe Medicines Co
drugs
baloxavir marboxil3
topics
Approval2Ophthalmology2

related stories

  • 2d agoNovo workforce down 13,000BioSpace
  • 2d agoNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • 2d agoSTAT+: A private equity-owned hospital chain is becoming a nonprofit. Is it just a bailout for investors?STAT
  • 3d agoSTAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programSTAT
  • 4d agoSTAT+: Lilly’s breast cancer combo wins approvalSTAT